Kwality Pharmaceuticals Ltd
KPLKwality Pharmaceuticals Ltd
KPL
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 31.94 | 4.14 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Kwality Pharmaceuticals Limited manufactures and exports pharmaceutical formulations for human and veterinary use.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 74.53 | 99.53 | 138.29 | 166.90 | 142.96 | 263.60 | 459.70 | 253.97 | 309.00 | 341.89 | ||||||||||
Raw Materials | 57.48 | 72.19 | 104.00 | 114.19 | 92.59 | 165.50 | 203.11 | 113.27 | 154.66 | 272.97 | ||||||||||
| Power & Fuel Cost | 2.31 | 2.81 | 2.76 | 3.71 | 4.20 | 6.13 | 11.07 | 12.98 | 17.23 | |||||||||||
| Employee Cost | 2.16 | 3.60 | 4.89 | 7.74 | 10.92 | 14.70 | 18.80 | 28.16 | 30.46 | |||||||||||
| Selling & Administrative Expenses | 5.35 | 8.91 | 11.07 | 13.71 | 19.59 | 41.70 | 48.74 | 32.64 | 30.91 | |||||||||||
| Operating & Other expenses | 1.85 | 1.91 | 3.10 | 11.22 | -2.22 | 5.12 | 2.80 | 19.79 | 14.70 | |||||||||||
EBITDA | 5.38 | 10.11 | 12.47 | 16.33 | 17.88 | 30.45 | 175.18 | 47.13 | 61.04 | 68.92 | ||||||||||
| Depreciation/Amortization | 1.69 | 2.51 | 2.98 | 3.12 | 4.43 | 6.49 | 10.69 | 14.96 | 19.56 | 18.54 | ||||||||||
| PBIT | 3.69 | 7.60 | 9.49 | 13.21 | 13.45 | 23.96 | 164.49 | 32.17 | 41.48 | 50.38 | ||||||||||
| Interest & Other Items | 1.22 | 1.95 | 2.21 | 2.29 | 2.52 | 2.68 | 2.92 | 6.61 | 10.39 | 10.98 | ||||||||||
| PBT | 2.47 | 5.65 | 7.28 | 10.92 | 10.93 | 21.28 | 161.57 | 25.56 | 31.09 | 39.40 | ||||||||||
| Taxes & Other Items | 0.92 | 2.28 | 2.75 | 3.35 | 2.60 | 6.12 | 41.57 | 6.21 | 7.30 | 10.53 | ||||||||||
| Net Income | 1.55 | 3.37 | 4.53 | 7.57 | 8.33 | 15.16 | 120.00 | 19.35 | 23.79 | 28.87 | ||||||||||
| EPS | 0.77 | 2.22 | 4.37 | 7.30 | 8.03 | 14.61 | 115.65 | 18.65 | 22.93 | 27.82 | ||||||||||
| DPS | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Kwality Pharmaceuticals Ltd | 38.76 | 4.14 | — |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare KPL with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
KPL has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJan 5, 2017
Dividend/Share
₹0.60
Ex DateEx Date
Jan 5, 2017
L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy. The company stated, 'This significant milestone underscores our commitment to delivering high-quality therapeutic solutions and marks an important step forward, as it is our first product from the biologics portfolio to be commercialized in both domestic and export markets', the firm stated. In addition, the company is actively engaged in discussions with leading domestic B2B companies to offer its PEGylated-Asparaginase on a CDMO (Contract Development and Manufacturing Organization) basis. These collaborations aim to leverage our manufacturing expertise, ensuring wider availability of this critical therapy. This approach not only strengthens local partnerships but also enhances patient access across various regions. Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers and sellers of and dealers in all kind of drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live
Net profit of Kwality Pharmaceuticals rose 35.74% to Rs 8.47 crore in the quarter ended September 2024 as against Rs 6.24 crore during the previous quarter ended September 2023. Sales rose 29.26% to Rs 90.03 crore in the quarter ended September 2024 as against Rs 69.65 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales90.0369.65 29 OPM %21.8421.87 - PBDT17.1813.05 32 PBT12.558.17 54 NP8.476.24 36 Powered by Capital Market - Live
Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live
Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Net profit of Kwality Pharmaceuticals rose 54.24% to Rs 8.36 crore in the quarter ended June 2024 as against Rs 5.42 crore during the previous quarter ended June 2023. Sales rose 18.72% to Rs 80.08 crore in the quarter ended June 2024 as against Rs 67.45 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales80.0867.45 19 OPM %21.6520.42 - PBDT15.1411.98 26 PBT11.127.20 54 NP8.365.42 54 Powered by Capital Market - Live
Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 13.11%, vs industry avg of 9.03%
Constant Market Share
Over the last 5 years, market share stayed at 0.08%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 25.74%, vs industry avg of 15.27%